IMDX
Price:
$5.61
Market Cap:
$150.58M
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A ...[Read more]
Industry
Medical - Diagnostics & Research
IPO Date
2015-12-30
Stock Exchange
NASDAQ
Ticker
IMDX
According to Insight Molecular Diagnostics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.72. This represents a change of 6.14% compared to the average of -3.50 of the last 4 quarters.
The mean historical PE Ratio of Insight Molecular Diagnostics Inc. over the last ten years is -4.70. The current -3.72 PE Ratio has changed 7.82% with respect to the historical average. Over the past ten years (40 quarters), IMDX's PE Ratio was at its highest in in the March 2023 quarter at 3.48. The PE Ratio was at its lowest in in the March 2021 quarter at -27.19.
Average
-4.70
Median
-3.93
Minimum
-16.75
Maximum
-0.49
Discovering the peaks and valleys of Insight Molecular Diagnostics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 787.49%
Maximum Annual PE Ratio = -0.49
Minimum Annual Increase = -83.79%
Minimum Annual PE Ratio = -16.75
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -4.55 | 787.49% |
| 2024 | -0.51 | -25.52% |
| 2023 | -0.69 | 41.13% |
| 2022 | -0.49 | -83.79% |
| 2021 | -3.01 | -42.42% |
| 2020 | -5.23 | 1.15% |
| 2019 | -5.17 | 55.90% |
| 2018 | -3.32 | -54.25% |
| 2017 | -7.25 | -56.73% |
| 2016 | -16.75 | 11.41% |
The current PE Ratio of Insight Molecular Diagnostics Inc. (IMDX) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.92
5-year avg
-1.85
10-year avg
-4.70
Insight Molecular Diagnostics Inc.’s PE Ratio is greater than C4 Therapeutics, Inc. (-4.74), less than Sangamo Therapeutics, Inc. (-0.47), less than Cybin Inc. (-1.47), greater than OmniAb, Inc. (-5.37), greater than Prelude Therapeutics Incorporated (-4.76), greater than Codexis, Inc. (-6.81), less than Armata Pharmaceuticals, Inc. (-0.98), less than Invivyd, Inc. (-3.07), less than PepGen Inc. (-1.32), less than Milestone Pharmaceuticals Inc. (-2.42),
| Company | PE Ratio | Market cap |
|---|---|---|
| -4.74 | $323.03M | |
| -0.47 | $62.14M | |
| -1.47 | $413.02M | |
| -5.37 | $270.34M | |
| -4.76 | $255.63M | |
| -6.81 | $218.15M | |
| -0.98 | $278.27M | |
| -3.07 | $102.20M | |
| -1.32 | $101.68M | |
| -2.42 | $109.08M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Insight Molecular Diagnostics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Insight Molecular Diagnostics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Insight Molecular Diagnostics Inc.'s PE Ratio?
How is the PE Ratio calculated for Insight Molecular Diagnostics Inc. (IMDX)?
What is the highest PE Ratio for Insight Molecular Diagnostics Inc. (IMDX)?
What is the 3-year average PE Ratio for Insight Molecular Diagnostics Inc. (IMDX)?
What is the 5-year average PE Ratio for Insight Molecular Diagnostics Inc. (IMDX)?
How does the current PE Ratio for Insight Molecular Diagnostics Inc. (IMDX) compare to its historical average?